Malaysian Genomics Resource Centre Bhd (XKLS:0155) ROCE %: 25.29% (As of Mar. 2026)


XKLS:0155 Malaysian Genomics Resource Centre Bhd XKLS:0155
47 GF Score
Price RM0.27
GF Value RM0.30
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Malaysian Genomics Resource Centre Bhd ROCE %?

Malaysian Genomics Resource Centre Bhd XKLS:0155 47 ROCE % is 25.29% as of Mar. 2026. GuruFocus rates XKLS:0155 with a GF Score™ of 47/100 and a GF Value™ of RM0.30 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Malaysian Genomics Resource Centre Bhd's annualized ROCE % for the quarter that ended in Mar. 2026 was 25.29%.

Malaysian Genomics Resource Centre Bhd  (XKLS:0155) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Malaysian Genomics Resource Centre Bhd ROCE % Related Terms

Malaysian Genomics Resource Centre Bhd ROCE % Historical Data

* Premium members only.

The historical data trend for Malaysian Genomics Resource Centre Bhd's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malaysian Genomics Resource Centre Bhd ROCE % Chart

Malaysian Genomics Resource Centre Bhd Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.20 -21.84 21.14 -14.89 -13.86

Malaysian Genomics Resource Centre Bhd Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.46 -9.59 7.62 -36.02 25.29
XKLS:0155
47GF Score
Malaysian Genomics Resource Centre Bhd XKLS:0155
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Malaysian Genomics Resource Centre Bhd ROCE % Calculation

Malaysian Genomics Resource Centre Bhd's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-2.391/( ( (22.355 - 3.557) + (18.709 - 3.004) )/ 2 )
=-2.391/( (18.798+15.705)/ 2 )
=-2.391/17.2515
=-13.86 %

Malaysian Genomics Resource Centre Bhd's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=4.404/( ( (18.709 - 3.004) + (21.396 - 2.273) )/ 2 )
=4.404/( ( 15.705 + 19.123 )/ 2 )
=4.404/17.414
=25.29 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 25.29% mean?
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a ROCE % of 25.29% as of Mar. 2026.
Is Malaysian Genomics Resource Centre Bhd's ROCE % too high?
Malaysian Genomics Resource Centre Bhd's current ROCE % is 25.29%. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's ROCE % compare to TMO and DHR?
Malaysian Genomics Resource Centre Bhd's ROCE % of 25.29% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Malaysian Genomics Resource Centre Bhd's current ROCE % is 25.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.30, compared to a current price of RM0.27 — trading 11.7% below its estimated fair value. The current ROCE % is 25.29%. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current ROCE % is 25.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?

Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be undervalued. The current stock price of RM0.27 is trading 11.7% below its estimated GF Value™ of RM0.30. GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:0155:

  • ROCE %: 25.29%
  • GF Value™: RM0.30 vs. price of RM0.27 (11.7% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Malaysian Genomics Resource Centre Bhd Business Description

Address Jalan Teknologi 3/6, 8F, Taman Sains Selangor 1, Kota Damansara (PJU5), Petaling Jaya, SGR, MYS, 47810
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
47GF Score

Get the complete analysis for XKLS:0155

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.27
Price
RM0.30
GF Value